About this trial
683,000 women are sexually assaulted annually in the United States, half of whom develop chronic posttraumatic stress disorder (PTSD) and thus have markedly increased risk for cannabis use disorder (CUD). The current proposal will test the acceptability, initial efficacy, and mechanisms underlying a novel digital therapeutic targeting risk for PTSD-CUD, which could address the critical need for PTSD-CUD prevention for the 100,000 women who annually present for emergency care after sexual assault. In this research context, the applicant will receive key training in multisite, emergency-care based randomized clinical trials (RCTs), advanced statistical analyses for RCTs and ecological momentary assessment data, biobehavioral mechanisms underlying PTSD-CUD prevention, and professional development, launching her independent research career focused on reducing the public health burden of PTSD-CUD among sexual assault survivors by leveraging digital therapeutics.
Eligibility criteria
Qualifiers
Women sexual assault survivors presenting for emergency care <72 hours post-assault at 1 of our 4 emergency care sites
English speakers
18+ years of age
Able to provide informed consent
Disqualifiers
Inability to provide informed consent (e.g., serious injury preventing the ability to hear, speak, or see to consent and participate, or other causes (e.g., diagnosed cognitive deficits, diagnosed dementia, asleep at time of screening)).
Prisoner
Currently pregnant
Lives with assailant and plans to continue to do so
Trial design
Treatments tested in this trial
- RISE Guide
- Relaxation Control
Treatment groups
Sponsors and collaborators
University of Nevada, Las Vegas
Lead sponsor
University of North Carolina, Chapel Hill
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
Hennepin HART
Collaborator
Tulsa Police Department Forensic Nursing
Collaborator
SAFE Austin Harbor Shelter
Collaborator